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Actomyosin polarisation through PLC-PKC triggers
symmetry breaking of the mouse embryo
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Establishment of cell polarity in the mammalian embryo is fundamental for the ﬁrst cell fate
decision that sets aside progenitor cells for both the new organism and the placenta. Yet the
sequence of events and molecular mechanism that trigger this process remain unknown.
Here, we show that de novo polarisation of the mouse embryo occurs in two distinct phases
at the 8-cell stage. In the ﬁrst phase, an apical actomyosin network is formed. This is a
pre-requisite for the second phase, in which the Par complex localises to the apical domain,
excluding actomyosin and forming a mature apical cap. Using a variety of approaches, we
also show that phospholipase C-mediated PIP2 hydrolysis is necessary and sufﬁcient to
trigger the polarisation of actomyosin through the Rho-mediated recruitment of myosin II to
the apical cortex. Together, these results reveal the molecular framework that triggers de
novo polarisation of the mouse embryo.
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Cell polarisation leading to the asymmetric distribution ofcellular components is critical for cell fate speciﬁcationand cellular rearrangements during development, as well
as for the maintenance of adult tissue homeostasis1–4. In contrast
to the development of embryos of many species, mammalian
embryos acquire cell polarity de novo at a species-speciﬁc
developmental stage. In the mouse embryo, cell polarisation
becomes established between the second and third day after fer-
tilisation, at the 8-cell stage, resulting in deﬁned apical and
basolateral domains5, 6. Consistent with canonical apicobasal
polarisation, the apical domain becomes enriched with the
Par3-Par6-aPKC complex, while the basolateral domain becomes
enriched with cell adhesion proteins7–9. This acquisition of cell
polarity coincides with embryo compaction, which leads to a
tighter embryonic geometry as a consequence of cell–cell contact
elongation and sealing of adjacent blastomeres10, 11.
Establishment of cell polarity at the 8-cell stage is a critical
morphogenetic event, as the presence of the apical polarity
domain directs the ﬁrst bifurcation of extra-embryonic and
embryonic lineages during the next cell divisions12. The cells that
inherit the apical domain are speciﬁed as trophectoderm (TE),
which will give rise to the placenta, while the cells that lack the
apical domain maintain pluripotency and develop as inner cell
mass, which will give rise to the foetus and yolk sac13. Conse-
quently, defective polarisation leads to altered cell fate speciﬁca-
tion, failure of blastocyst formation and developmental arrest14,
15. Despite its major importance, it remains unknown how cell
polarity becomes ﬁrst established in the mammalian embryo.
Here, we demonstrate that cell polarisation in the mouse
embryo is initiated by PLC-mediated PIP2 hydrolysis that acti-
vates protein kinase C (PKC), and in turn RhoA, leading to
cortical accumulation of actomyosin. By using a variety of
approaches to eliminate PKC function and optogenetic techni-
ques to activate it locally, we show that ectopic activation of PKC
is sufﬁcient to give a local enrichment of actin and phosphory-
lated myosin light chain. Induction of this cytoskeletal asymmetry
is an absolute pre-requisite for the cortical enrichment of the Par
complex to establish cell polarity and form a mature apical cap.
These ﬁndings provide a molecular framework for how the
reorganisation of the actomyosin network triggers cell polarisa-
tion in a temporally controlled manner in the mouse embryo.
Results
Actomyosin and Par complex dynamics deﬁne two phases of
cell polarisation during mouse embryogenesis. The actomyosin
network and the Par complex represent two conserved systems
used to establish cell polarity in many model systems3, 16–18. We
therefore ﬁrst wished to determine the behaviour of these mole-
cular complexes as cell polarity becomes established and as cells
compact in the mouse embryo. To this end, we examined their
localisation from the early to the late 8-cell stage using the angle
between adjacent blastomeres (inter-blastomere angle or IEA) as
a measure of the extent of compaction, and thus temporal pro-
gression through the 8-cell stage, and F-actin and Pard6 as
respective markers of actomyosin and the Par complex
(Supplementary Fig. 1a). We found that actomyosin and the Par
complex became polarised following a step-wise pattern. Analysis
of the circumferential distribution of F-actin and Pard6 in cell-
contact and cell-contact-free regions revealed that during the
early 8-cell stage (within 1 h post cell division) to mid 8-cell stage
(3–4 h post cell division), F-actin became gradually localised
apically, while Pard6 remained distributed equally around the cell
cortex (Fig. 1a–c and Supplementary Fig. 1b). Only at the mid-
late 8-cell stage (5–8 h post cell division), did Pard6 begin to
accumulate apically. Upon apical enrichment of Pard6, F-actin
became redistributed to surround the Par apical domain in a
ring-like structure (Fig. 1a–c). To conﬁrm this sequence of events,
we also examined the localisation of PKCζ, another essential
component of the Par complex (Supplementary Fig. 1c).
As an alternative readout of actomyosin localisation, we
injected messenger RNA (mRNA) for GFP-tagged myosin
regulatory light chain (GFP-MRLC) at the 2-cell stage and
followed subsequent development. In agreement with the above
observation, this revealed that GFP-MRLC became enriched at
the apical domain much earlier than Pard6, and subsequently
redistributed to the periphery of the Pard6 domain upon Pard6
apical enrichment (Supplementary Fig. 1d–f). To further conﬁrm
that the apical enrichment of actomyosin precedes apical domain
maturation, we compared the localisation of F-actin during the
8-cell stage to the localisation of another two conserved apical
domain markers, Crb319 and Ezrin20 by double-immunostaining
or time-lapse imaging. In both cases, we found that F-actin
polarised to the cell-contact-free surface before any apical
markers (Supplementary Fig. 1g–i). Collectively, these results
indicate that de novo polarisation of the mouse embryo occurs in
two phases: in the ﬁrst phase, the actomyosin network polarises to
the cell-contact-free surface during embryo compaction. In the
second phase, Par proteins, together with other conserved apical
components, become polarised and the actomyosin network
forms a ring structure around the Par-enriched domain once
compaction is completed (Fig. 1d).
Asymmetry of the functional actomyosin network is required
for Par complex polarisation. Since the above observations
indicated that apical localisation of the actomyosin network
precedes localisation of Par complex components, we next wished
to determine the functional requirement of actomyosin asym-
metry for the apical enrichment of the Par complex. To this end,
we ﬁrst attempted to use RNAi to deplete MRLC as a way of
inhibiting actomyosin activity. We found that although we were
able to deplete over 74% of the mRNA of the predominant MRLC
isoform expressed at the early cleavage stages21, 22, its protein
levels remained largely unchanged, most likely reﬂecting a large
maternal storage (Supplementary Fig. 2a, b). To circumvent this
difﬁculty, we turned to use pharmacological inhibitors. As con-
tractility has been viewed as a general function of actomyosin in
the regulation of cellular morphogenesis23 and recently it has
been suggested to be required for compaction24, we ﬁrst sought to
investigate whether actomyosin contractility is required for con-
structing the apical domain. To this end, we used blebbistatin, a
potent and selective inhibitor of myosin II ATPase activity25. We
applied blebbistatin at the beginning of the 8-cell stage, to avoid
inhibiting the preceding cytokinesis, and determined cell polarity
by examining the localisation of Pard6 and F-actin, and com-
paction by measuring IEA. We found that although blebbistatin
treatment abolished compaction, establishment of apical domain
remained unaffected, as both F-actin and Pard6 remained
polarised to the cell-contact-free domain (Fig. 2a–d). The result
was the same regardless of whether we increased the blebbistatin
concentration or extended the timing of the treatment (Supple-
mentary Fig. 2c), suggesting that actomyosin contractility,
although critical for compaction, is dispensable for establishment
of the apical domain.
To determine whether apical enrichment of actomyosin is
required for Par complex, we treated 4–8-cell stage embryos with
ML-7 (an inhibitor of MLCK26) or Y-27632 (an inhibitor of
ROCK27) to abolish the phosphorylation-mediated assembly of
myosin II ﬁlament, or latrunculin B (LatB) to potently destroy the
actin meshwork28. We found that, contrary to blebbistatin
treatment, all three inhibitors signiﬁcantly abolished Pard6’s
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Fig. 1 Dynamics of actomyosin and Pard6 polarisation at the 8-cell stage. a Mouse embryos were ﬁxed at early, mid and late 8-cell stage, and
immunostained for F-actin and Pard6. Arrowheads indicate the magniﬁed blastomeres. b Circumferential line proﬁles of F-actin and Pard6 ﬂuorescence
intensity in embryos from (a). Yellow indicates cell–cell contact regions and blue cell-contact-free domain. Smoothened data were displayed as coloured
curves to show the pattern of the signal. c Cell-contact-free enrichment of F-actin and Pard6 plotted against the IEA in embryos from (a). Each dot
represents an individual measurement. N= 25 embryos, three independent experiments. LOWESS plot were used to display the tendency of different
datasets. The shadow indicates the 95% conﬁdence interval. d Summary of the different phases of polarisation during the 8-cell stage. During the ﬁrst
phase, embryos start compacting and actomyosin becomes polarised to the apical domain. During the second phase, embryos are already compacted and
apical domain components, including Pard6 polarise apically. All scale bars, 15 μm
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cell-contact-free enrichment (Fig. 2a–d and Supplementary
Fig. 2d). ML-7 and LatB treatment also inhibited compaction
and actomyosin asymmetry (Fig. 2a–d). To conﬁrm the effects of
the inhibitors, we examined the pattern of phosphorylated MRLC
or F-actin after different inhibitor treatments. We found that, at
the late 8-cell stage, a similar level of phosphorylated MRLC
remained enriched at the cell-contact-free domain in blebbistatin-
treated compared to control blastomeres, indicating that
blebbistatin did not affect actomyosin activation or polarisation
(Supplementary Fig. 2e, f). On the contrary, both ML-7 and
Y-27632 treatment led to a reduction of phosphorylated MRLC at
the cell-contact-free surface, with a stronger decrease resulting
from ML-7 treatment (Fig. 2e, f and Supplementary Fig. 2g, h).
LatB treatment strongly disturbed F-actin organisation and
resulted in its patchy distribution (Fig. 2a).
To unequivocally determine whether the apically polarised
actomyosin is indeed essential for Par complex recruitment as the
above results suggested, we next wished to destabilise actomyosin
structure after actomyosin had become polarised and before the
recruitment of Par complex. To this end, we applied ML-7 at mid
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8-cell stage (3–4 h post cell division when embryos were
compacted) and determined the localisation of actomyosin and
the Par complex at the late 8-cell stage. We also measured the IEA
to monitor the change of compaction status. We found that
delayed ML-7 treatment did not affect compaction, as the IEA
remained similar between the ML-7- and DMSO (control)-
treated groups (Supplementary Fig. 2i, j). However, the enrich-
ment of GFP-MRLC at the cell-contact-free domain was
abolished in the ML-7-treated group (Supplementary Fig. 2i, k),
indicating the effectiveness of delayed ML-7 treatment in
disturbing actomyosin organisation. More importantly, the
recruitment of Pard6 to the cell-contact-free surface was strongly
inhibited (Supplementary Fig. 2i, l). Taken together, these results
indicate that the intact organisation of an apically polarised
actomyosin network, which pioneers apical domain formation, is
required for Par polarisation.
Activation of myosin triggers cell polarisation at the early 8-
cell stage. How cell polarity is speciﬁcally induced at the 8-cell stage
remains unknown. Since our results indicated that the polarised
organisation of actomyosin precedes and is required for polarisation
of the Par complex, we next wished to determine how and when the
actomyosin network becomes polarised. Given that myosin acti-
vation is required for actomyosin polarisation (Fig. 2a–d), we
considered that myosin could be activated and polarised speciﬁcally
at the 8-cell stage or, alternatively, myosin could be active
throughout pre-implantation development, but at the 8-cell stage,
an asymmetric inhibitory signal could lead to its polarised activity.
To address this question, we examined the localisation of phos-
phorylated MRLC in relation to F-actin from the 4-cell to the late
8-cell stage. We found that the ﬁrst cortical localisation of phos-
phorylated MRLC could be detected at the early 8-cell stage, but not
at any time throughout 4-cell stage (Fig. 2g, h and Supplementary
Fig. 2m, n). By the mid 8-cell stage, phosphorylated MRLC became
enriched at the cell-contact-free cortex of all 8-cell blastomeres in a
similar fashion to GFP-MRLC (Fig. 2g, h and Supplementary
Fig. 1d–f). The level of phosphorylated MRLC progressively
increased until the late 8-cell stage, at which point phosphorylated
MRLC formed a ring-like structure and co-localised with the cor-
tical meshwork of F-actin (Fig. 2g, h). These results indicate that the
activation and polarisation of myosin network initiates cell polar-
isation at the early mid 8-cell stage.
PLC-mediated PKC activity is critical for cell polarisation. PKC
family members are known to play a role in compaction29, 30.
However, whether PKC is also required to establish cell polarity
in the mouse embryo remains currently unknown. To test if PKC
is required for cell polarisation, we wished to inhibit all the
multiple PKC isoforms expressed in mouse embryos at this
stage31. To this end, we used two pan-PKC inhibitors highly
selective for conventional PKCs (cPKCs) and novel PKCs32, 33,
sphingosine and calphostin C, and applied them to embryos at
the 4- to 8-cell stage transition. We found that both sphingosine
and calphostin C treatments prevented compaction as well as the
cell-contact-free surface enrichment of F-actin and Pard6
(Fig. 3a–f), suggesting that PKC is important not only for com-
paction but also for cell polarisation in the mouse embryo.
The canonical activation of cPKCs requires both diacylglycerol
(DAG) and inositol triphosphate (IP3), which in turn triggers
intracellular calcium release required for cPKC activation34. DAG
and IP3 are the products of the hydrolysis of the membrane
phospholipid PtdIns(4,5)P2 (PIP2), a process catalysed by PLC.
To test if this pathway is responsible for PKC activation, we
prevented DAG production from PIP2 hydrolysis by applying a
highly selective pan-PLC inhibitor (U73122)35 from the 4-cell
stage onwards, and assessed cell polarity at the late 8-cell stage
(Fig. 3g). In agreement with ﬁndings above, U73122 treatment
prevented the establishment of the apical domain and resulted in
compaction failure (Fig. 3h–l; Supplementary Fig. 3a–c and
Supplementary Movie 1, 2). Although establishment of cell
polarity was inhibited, blastomeres were still able to undergo
cytokinesis (Supplementary Fig. 3a, d, e). At the 16-cell stage,
polarisation of the outer cells is involved in activating expression
of the key trophectoderm transcription factor, Cdx212, 36. To
examine whether cell polarisation was functionally hindered and
so affected cell fate speciﬁcation and differentiation into the
trophectoderm lineage, we examined the expression of Cdx2. We
found that U73122-treatment abolished Pard6 polarisation and
Cdx2 expression, in contrast to control embryos in which outer
cells showed polarised Pard6 and Cdx2 expression as previously
described37, 38 (Supplementary Fig. 3f, g).
To determine whether the effect of PLC inhibition is the
speciﬁc result of DAG depletion and lack of PKC activation, we
co-applied the PLC inhibitor U73122 and the DAG analogue and
PKC activator, 1-oleoyl-2-acetyl-sn-glycerol (OAG)39 to deter-
mine if this would rescue the observed phenotype. We found that
in all embryos co-treated with OAG, blastomeres became
polarised, indicating that the defect in apical domain formation
caused by PLC inhibition was rescued by the activation of PKC
(Fig. 3h–l).
To further conﬁrm that PLC-catalysed PIP2 hydrolysis acts
upstream of PKC to trigger cell polarisation, we used a dominant-
negative genetic construct as an alternative way to directly inhibit
PIP2 hydrolysis. We overexpressed the ﬂuorescent-tagged PH
domain of PLCδ1 (Plcd1-PH-Ruby), a dominant-negative form
of PLC isotypes (PLC-DN), which upon overexpression blocks
PIP2 hydrolysis by PLC as a result of competitive binding to
Fig. 2 A polarised and active actomyosin network is required for Par complex polarisation. a 8-cell stage (blebbistatin, LatB group and its control) or 4–8
cell stage embryos (ML-7 and its control) were treated with DMSO, blebbistatin, ML-7 or LatB, and ﬁxed at the late 8-cell stage. Early 8-cell stage embryos
treated with DMSO were also ﬁxed as a control. Embryos were immunostained for F-actin and Pard6. b, c Cell-contact-free enrichment of F-actin (b) or
Pard6 (c) as a function of the IEA in embryos from (a). Each dot represents an individual measurement. d Percentage of polarised embryos in the groups of
(a). The number of embryos per category is indicated. Embryos that did not show any blastomere with the enrichment of F-actin and Pard6 at the cell-
contact-free surface were considered non-polarised. Otherwise embryos were classiﬁed as polarised. Data are shown as a contingency table.
****p< 0.0001, NS= not signiﬁcantly different, Fisher’s exact test (six independent experiments). e DMSO and ML-7-treated embryos immunostained for
ppMRLC. f Quantiﬁcation of ppMRLC cell-contact-free cortical enrichment in ML-7-treated and control embryos. Each dot represents an individual
measurement. Data are shown as individual data points with Box and Whiskers graph (bottom: 25%; top: 75%; line: median; whiskers: min to max).
****p< 0.0001, Mann–Whitney test. N= 10 embryos for DMSO and N= 12 embryos for ML-7, four independent experiments. g ppMRLC and F-actin
staining from the late 4-cell stage to the late 8-cell stage. The ppMRLC signal intensity of the indicated blastomeres is plotted in 3D. White stars indicate
the cell-contact-free surface. Arrowheads indicate cortical localisation of ppMRLC. h Quantiﬁcation of ppMRLC enrichment at the cell-contact and
cell-contact-free domains from the late 4-cell stage to the late 8-cell stage. Data are shown as mean± s.e.m. For all panels, squares indicate the magniﬁed
regions. N= 32 measurements from 7 late 4-cell stage embryos; N= 69 measurements from 11 early 8-cell stage embryos; N= 86 measurements from 11
mid 8-cell stage embryos; N= 50 measurements from 13 late 8-cell stage. All scale bars, 15 μm
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PIP240, 41. PLC-DN mRNA was injected into both blastomeres at
the 2-cell stage (and only Ruby mRNA in control embryos) and
the localisation of F-actin and Pard6 were examined at the late 8-
cell stage (Fig. 3m). We found that overexpression of PLC-DN
inhibited formation of the apical domain at the late 8-cell stage
(Fig. 3n–p). Despite the polarisation failure, cytokinesis still took
place (Supplementary Fig. 4a, b). Overexpression of PLC-DN also
blocked compaction (Fig. 3n; Supplementary Fig. 4a and
Supplementary Movie 3, 4), consistent with the pharmacological
inhibition of PLC (Fig. 3i, j and Supplementary Fig. 3a). An
equivalent impairment of Cdx2 expression was observed in PLC-
DN overexpressing embryos at the 16-cell stage, indicating that
apical polarisation is functionally abolished by PLC-DN (Supple-
mentary Fig. 4c, d). To determine the speciﬁcity of the PLC-DN,
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we also carried out a rescue experiment by applying the PKC
activator OAG at the early 8-cell stage to PLC-DN expressing
embryos. We found that OAG treatment was able to partially
rescue the polarity defect arising from PLC-DN expression
(Fig. 3n–p).
The above results indicated that the PLC–PKC signalling
pathway and MRLC phosphorylation are required for establishing
cell polarity at the 8-cell stage. However, whether MLCK-
mediated phosphorylation of MRLC is triggered downstream of
the PLC–PKC activation remained unknown. To address this
question, we next examined the distribution of phosphorylated
MRLC in PLC-DN expressing embryos and also in 8-cell embryos
treated with sphingosine, calphostin C or U73122. We found that
the level of phosphorylated MRLC at the cell-contact-free surface
decreased following all of these treatments when compared to
control embryos (Fig. 4a–h). Together, these results indicate that
PLC–PKC signalling controls the level of phosphorylated MRLC
on the apical domain in the ﬁrst phase of cell polarisation.
Ectopic PKC activation induces premature actomyosin polar-
isation but not polarisation of Par complex components. Since
our results demonstrated that PLC–PKC signalling is required for
the establishment of cell polarity at the 8-cell stage, we next
wished to determine whether upregulating PKC activity would be
sufﬁcient to augment cell polarisation. To this end, we used two
different methods to activate PKC: treatment with the PKC
activator OAG and overexpression of constitutively activate
PKCɑ (PKCɑ-A25E)42. We applied OAG at the early 8-cell stage
and found that while in control embryos Pard6 was restricted to
the central part of the contact-free surface (mean surface coverage
ratio (SCR) of 57.3%; Fig. 5a, b), treatment with OAG led to a
signiﬁcant increase in Pard6 SCR (84.8%) at the late 8-cell stage,
and in certain cases, Pard6 even expanded throughout the entire
contact-free surface (Fig. 5a, b). Prolonged OAG treatment up to
the 16-cell stage induced an expansion of the Pard6 domain to the
whole cell membrane, not only of outer but also of inner cells
(Supplementary Fig. 5a, b). To determine if PKC activation could
induce premature cell polarisation before 8-cell stage, we applied
OAG at the early 4-cell stage. OAG treatment led to premature
compaction, as previously described42, and resulted in the
enrichment of both F-actin and phosphorylated MRLC at the
cell-contact-free surface (Fig. 5c, e). However, although acto-
myosin was robustly polarised, no enrichment of Pard6 at the
cell-contact-free surface could be observed (Fig. 5c–e and Sup-
plementary Fig. 5c). A similar result was observed following
PKCɑ-A25E overexpression, which induced a polarised dis-
tribution of F-actin and GFP-MRLC towards the cell contact-free
surface but not of Pard6 (Fig. 5f–h and Supplementary Fig. 5d).
This indicates that although PKC activity is sufﬁcient to initiate
premature cell polarisation, and other factors are required to
polarise Par complex components.
PKC controls actomyosin polarisation by local activation. To
determine if a local activation of PKC triggers local actomyosin
activation, we wished to apply a photo-activatable system to
achieve precise activation of PKC. To this end, we used the CRY2
and CIB1 protein system, in which blue light triggers the binding
of CRY2 and CIB1 as a heterodimer43, 44. We fused CIB1 with
Zsgreen to visualise its localisation and the K-Ras CAAX motif to
provide a membrane localisation signal. CRY2 was fused with the
kinase domain of PKCɑ (CRY2-PKC-KD) and with mCherry, to
visualise its localisation (Fig. 5i). We found that within 10 min of
illumination with blue light in a deﬁned cell contact-free region,
CRY2-PKC-KD was recruited to this region, indicative of the
translocation of the PKC kinase domain to the cell membrane
and the effective binding of CRY2 and CIB1 (Fig. 5j; Supple-
mentary Fig. 6a, b and Supplementary Movie 5). The cortical
accumulation of CRY2-PKC-KD led to an enrichment of F-actin
and phosphorylated MRLC within but not outside of the illu-
minated area (Fig. 5k). In contrast, no phosphorylated MRLC
could be detected on the cell cortex without blue-light illumina-
tion. Blue light was also insufﬁcient to trigger phosphorylated
MRLC upregulation in embryos expressing constructs without
the PKC kinase domain (Supplementary Fig. 6c, d). Together
these multiple control conditions suggest that the upregulation of
actomyosin recruitment was caused by PKC activation rather
than any other non-speciﬁc effect. In agreement with our results
above, the localisation of Pard6 remained unaffected. Together,
these results show that local activation of PKC directly leads to a
local activation of actomyosin but not Par complex polarisation.
Inhibition of PLC–PKC abolishes MRLC apical localisation.
Since the above results demonstrated that PKC mediates local
activation of actomyosin, we next wished to uncover the
mechanism behind it. To this end, we ﬁrst tested whether
PLC–PKC inhibition leads to a decrease in the level of cortical
myosin. We found that inhibition of PLC–PKC signalling, either
by overexpression of PLC-DN or by inhibition of PKC, abrogated
the accumulation of GFP-MRLC at the cell-contact-free cortex
(Fig. 6a–f). It has been shown that MRLC has to be assembled
into the myosin II complex to be recruited to the cortex and its
phosphorylation is a pre-requisite for myosin II assembly45, 46. In
agreement, we found that MLCK inhibition signiﬁcantly reduced
MRLC accumulation to the cell cortex (Fig. 6g, h). In light of
Fig. 3 PLC–PKC activity is essential for polarisation at the 8-cell stage. a Scheme of the inhibitor (sphingosine, calphostin C) treatment. (b) DMSO,
sphingosine and calphostin C-treated embryos immunostained for F-actin and Pard6. c, d Cell-contact-free enrichment of F-actin (c) or Pard6 (d) as a
function of the IEA in embryos from (b). Each dot represents an individual measurement. e Percentage of polarised embryos in the groups of (b). The
number of embryos per category is indicated. Embryos that did not show any blastomere with the enrichment of F-actin and Pard6 to the cell-contact-free
surface were considered non-polarised. Otherwise embryos were classiﬁed as polarised. Data are shown as a contingency table. ****p< 0.0001, Fisher’s
exact test. f Quantiﬁcation of polarisation in embryos from (b). Data are shown as mean± s.d. ****p< 0.0001, unpaired two-tailed Student’s t test (three
independent experiments). g Scheme of U73122 treatment and OAG rescue experiment. h DMSO, U73122 and U73122 + OAG-treated embryos
immunostained for F-actin and Pard6. i, j Cell-contact-free enrichment of F-actin (i) or Pard6 (j) as a function of the IEA in embryos from panel h. Each dot
represents an individual measurement. k Percentage of polarised embryos in the groups of (h). The number of embryos per category is indicated. Data are
shown as a contingency table. ****p< 0.0001, NS= not signiﬁcantly different, Fisher’s exact test. l Quantiﬁcation of polarisation in embryos from (h). Data
are shown as mean± s.d. ***p< 0.001, ****p< 0.0001, NS= not signiﬁcant different, Kruskal–Wallis test and Dunn’s multiple comparisons test (two
independent experiments). m Scheme of the PLC-DN overexpression and OAG rescue experiment. n Ruby and PLC-DN overexpressing embryos±OAG
immunostained for F-actin and Pard6. o Percentage of polarised embryos in the groups of (n). The number of embryos per category is indicated. Data are
shown as a contingency table. ****p< 0.0001, **p< 0.01, Fisher’s exact test. p Quantiﬁcation of polarisation in embryos from (n). Data are shown as mean
± s.d. **** p< 0.0001, **p< 0.01, *p< 0.05, Kruskal–Wallis and Dunn’s multiple comparisons tests (two independent experiments). All scale bars, 15 μm
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these ﬁndings, we hypothesised that the reduction of MRLC
cortical accumulation observed upon PLC–PKC inhibition might
be caused by a reduction of MRLC di-phosphorylation. To
address this possibility, we constructed a phosphomimetic mutant
of GFP-MRLC (GFP-MRLC-DD), in which the two MLCK
phosphorylation sites (T18, S19) were mutated to aspartic acid
(D) residues to mimic the di-phosphorylated conformation as this
mutant has been shown to bypass the phosphorylation step
required for the assembly of myosin ﬁlaments47, although it is
inefﬁcient in recapitulating all of the functions of MRLC48. In line
with these observations, we found that GFP-MRLC-DD could still
accumulate at the cortex despite MLCK inhibition (Fig. 6h, i). In
g
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contrast, however, this mutant of GFP-MRLC was unable to gain
cortical localisation following overexpression of PLC-DN or
treatment with U73122 or sphingosine (Fig. 6a–f). Together, these
results indicate that PLC–PKC signalling regulates the recruit-
ment of MRLC to the apical cortex independently of MLCK-
mediated MRLC phosphorylation, and that this apical localisation
is necessary for the establishment of cell polarity at the 8-cell
stage.
RhoA regulates MRLC apical localisation downstream of
PKC–PLC. The above ﬁndings indicated that PKC activity con-
trols the cortical recruitment of MRLC independently of MLCK-
mediated MRLC phosphorylation and that both signalling path-
ways are required for de novo polarisation of the embryo at the 8-
cell stage. However, the mechanism through which PKC controls
MRLC localisation in the mouse embryo still remained unknown.
We hypothesised that Rho proteins (Rho GTPases RhoA/B/C)
might be potential candidates since they are involved in 8-cell
stage polarisation, although the mechanism through which they
might act has remained undetermined49, 50. To address if Rho
proteins regulate MRLC localisation, we injected GFP-MRLC
mRNA at the 4-cell stage, treated embryos with the Rho proteins
inhibitor C3-transferase51 at the 4- to 8-cell stage transition and
examined the localisation of MRLC and Pard6 at the late 8-cell
stage. All embryos in the control group had polarised GFP-MRLC
and Pard6, while C3-transferase treatment strongly suppressed
GFP-MRLC and Pard6 recruitment to the cell-contact-free
domain (Supplementary Fig. 7a–d). To test whether Rho GTPa-
ses are the downstream effector of PLC–PKC signalling during
cell polarisation, we used Forster resonance energy transfer
(FRET)-based RhoA sensor (Raichu-RhoA-CR)52. We found that
in the DMSO-treated control embryos, RhoA activity was gra-
dually enriched in the cell-contact-free domain during compac-
tion (Supplementary Fig. 7e, f), but U73122 treatment strongly
abolished its polarisation to the cell-contact-free surface (Sup-
plementary Fig. 7e, f), suggesting that PLC–PKC activity is
responsible for polarising RhoA activity to the apical domain. To
determine whether RhoA is the major component downstream of
PLC–PKC to establish cell polarity, we wished to examine whe-
ther constitutively activate RhoA (RhoA-Q63L) could rescue the
polarity defect caused by PLC–PKC inhibition. To this end, PLC-
DN mRNA was injected at the 2-cell stage to block PIP2
hydrolysis and, at the 4-cell stage, two blastomeres were injected
with constitutively active RhoA-Q63L mRNA and GFP-MRLC
mRNA to follow myosin II localisation (Fig. 7a). In agreement
with our experiments above, we found that overexpression of
PLC-DN inhibited polarisation of Pard6 and GFP-MRLC when
compared to control embryos (Fig. 7b–d). Remarkably, blas-
tomeres in which RhoA-Q63L was overexpressed regained
asymmetrically localised Pard6 and MRLC (Fig. 7b–d). To con-
ﬁrm these results further, we used the PLC inhibitor U73122, as
an alternative approach to inhibit PLC–PKC signalling. To this
end, we ﬁrst cultured 4-cell stage embryos in the presence of
U73122 (or in DMSO as a control) and, at the mid to late 4-cell
stage, injected two blastomeres with GFP-MRLC mRNA alone
(control) or with GFP-MRLC and RhoA-Q63L mRNAs (experi-
mental group) (Fig. 7e). In accord with the above PLC-DN rescue
experiment, we found that Pard6 and MRLC regained their
polarised cortical localisation in blastomeres overexpressing
RhoA-Q63L (Fig. 7f–h).
Finally, to determine whether RhoA activation at the 4-cell
stage could advance the timing of Pard6 polarisation, we
constructed a controllable RhoA photoactivation system in which
the CRY2 construct was fused with RhoA mutant Q63L-C190R.
Such RhoA mutant remains constitutively active but loses the
ability to translocate to the membrane by itself, and thus cannot
activate downstream effectors53. We found that blue-light
activation effectively upregulated cortical localisation of phos-
phorylated MRLC. This upregulation was not observed in a
membrane region not exposed to light (Supplementary Fig. 6d),
conﬁrming the speciﬁcity of our system. However, blue-light-
mediated activation of RhoA was insufﬁcient to recruit Pard6,
similar to our ﬁndings when PKC was activated at this stage
(Supplementary Fig. 7g).
Taken all together, our results indicate that PLC–PKC
signalling is involved in the initiation of cell polarity in the
mouse embryo at the 8-cell stage by regulating cortical
localisation of MRLC via RhoA activation (Fig. 7i).
Discussion
Establishing cell polarity is a critical step in embryo development. In
the mouse embryo, the establishment of cell polarity is a
pre-requisite for the ﬁrst-lineage segregation to set apart the plur-
ipotent progenitor cells of the foetus from the progenitors of the
placenta12. Here, we demonstrate that cell polarisation in the mouse
embryo can be divided into two phases: an initiation phase and a
maturation phase. In the initiation phase, actomyosin becomes
polarised to the apical domain at the 8-cell stage laying the foun-
dation for the polarisation of Par complex to the apical domain,
excluding actomyosin and forming a mature apical cap in the
maturation phase. We also demonstrate that PLC–PKC signalling is
necessary and sufﬁcient to trigger actomyosin polarisation through
Fig. 5 Ectopic activation of PKC expands the apical domain and induces premature actomyosin polarisation. a 8-cell stage embryos treated with DMSO or
OAG and immunostained for F-actin and Pard6. Yellow arrows indicate the borders of the cell-contact-free domain and white arrows indicate the borders
of the Pard6 apical domain. b Quantiﬁcation of the Pard6 surface coverage rate in embryos from (a). The surface coverage rate is calculated as the ratio
between the length of Pard6 positive domain and the length of the cell-contact-free surface. Data are shown as individual data points with Box and
Whiskers graph. ****p< 0.0001, two-tailed unpaired Student’s t test. N= 8 embryos for DMSO and N= 6 embryos for OAG, four independent
experiments. c 4-cell stage embryos treated with DMSO or OAG and immunostained for F-actin, ppMRLC and Pard6. Arrowheads indicate apically
polarised F-actin or ppMRLC. d Cell-contact-free enrichment of F-actin and Pard6 as a function of the IEA in embryos from (c). Dots represent individual
measurements. e Quantiﬁcation of cell-contact-free cortical enrichment of ppMRLC in embryos from (c). Data are shown as individual data points with a
Box and Whiskers graph (bottom: 25%; top: 75%; line: median; whiskers: min to max). ****p< 0.0001, Mann–Whitney test. N= 18 embryos for DMSO and
N= 10 embryos for OAG, six independent experiments. f 4-cell stage embryos expressing GFP-MRLC or GFP-MRLC + PKCɑ-A25E in two blastomeres
were immunostained for GFP, F-actin and Pard6. Arrowheads indicate the injected blastomeres. g, h Quantiﬁcation of cell-contact-free enrichment of GFP-
MRLC (g) or F-actin (h) in embryos from (f). Data are shown as individual data points with Box and Whiskers graph (bottom: 25%; top: 75%; line: median;
whiskers: min to max). ***p< 0.001, ****p< 0.0001, Mann–Whitney test. N= 6 embryos, three independent experiments. i Scheme of the PKC-localised
activation using the CRY2-CIB1 photoactivatable system. j Time-lapse snapshots of the localisation of CRY2-PKC-KD under localised blue-light
illumination. k Blastomeres expressing CIB1-Zsgreen-CAAX and CRY2-PKC-KD were regionally illuminated using a 458 nm wavelength and
immunostained for F-actin, ppMRLC and Pard6. Arrowheads or dotted circles indicate the illuminated region. Squares indicate the magniﬁed regions. (N=
24 embryos, 11 independent experiments). All scale bars, 15 μm
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the Rho-mediated recruitment of myosin II to the apical cortex.
Together, this reveals the molecular circuitry that triggers de novo
polarisation of the mouse embryo at the 8-cell stage.
What initiates mouse embryo polarisation at the 8-cell stage
has remained unknown. It has been suggested that this might
result from changes in cell adhesion because the adherens junc-
tion component E-cadherin antagonises actomyosin at the
basolateral domain, acting as a negative regulator of apical
domain formation54. However, other lines of evidence have
suggested that cell–cell contacts might be insufﬁcient to trigger
cell polarisation because, for example, chimeras between 8-cell
stage and earlier stage blastomeres show cellular polarisation
exclusively in the 8-cell stage blastomeres55. In addition, it has
been shown that the apical domain could be established in the
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absence of E-cadherin or cell–cell contacts12, 56 and that micro-
tubules might be able to induce apical domain formation in a
small proportion of cells independent of cell contact as a back-up
mechanism57. Similarly, as polarisation happens in parallel to
compaction, it has been postulated that compaction is required
for apical domain assembly. Here, we show that compaction and
polarisation are independent events as compaction can be spe-
ciﬁcally interfered without affecting polarisation, and vice versa.
Therefore, the polarity phenotype caused by inhibition of
PLC–PKC, MLCK or RhoA is speciﬁc to apical domain assembly,
rather than a secondary effect of affecting compaction. The results
we present here strongly indicate that the accumulation of acto-
myosin at the apical cortex of blastomeres at the early 8-cell stage
is essential to set up cell polarity enabling the apical localisation of
the Par complex. Our results also provide evidence that PKC is
both necessary and sufﬁcient to induce this asymmetric locali-
sation of the actomyosin network as the ﬁrst manifestation of
cellular asymmetry. The early mouse embryo has multiple iso-
forms of PKC provided by maternally expressed genes, and
therefore to eliminate PKC function genetically would require a
complex combination of maternal and zygotic knockouts of
multiple genes. To overcome this difﬁculty, we have applied a
combination of speciﬁc pharmacological inhibitors, of either PKC
or its activator PLC and dominant negative mutant constructs to
eliminate PLC–PKC function speciﬁcally. Moreover, we could
activate PKC by application of OAG, which broadened the
domain of PKC activity and hence actomyosin activation, or by
using an optogenetic approach to activate PKC and actomyosin
locally. Application of these multiple approaches has allowed us
to reveal that PKC is a rate-limiting factor for actomyosin
polarisation, and thus PKC activity acts as a trigger to initiate
polarisation at the 8-cell stage.
But how does PKC induce an asymmetric localisation of
actomyosin? It is known that myosin is activated via phosphor-
ylation, which is needed for its assembly into myosin ﬁlaments
and subsequent cortical recruitment46. To generate a stabilised
cortical myosin network, the actin cytoskeleton also needs to be
assembled into a cortical actin meshwork, which is mediated by a
number of actin cross-linking proteins, such as formins and
Arp2/358. In the muscle, PKC is known for its ability to control
myosin localisation via phosphorylation59. Our results indicate
that in the early pre-implantation mouse embryo PKC regulates
myosin localisation through the activity of Rho GTPases. As
RhoA is a common activator of formins, one possibility is that
PKC controls myosin II cortical recruitment through formin-
mediated actin reorganisation. It will be of future interest to
reveal the dynamics of the apical actin meshwork and actin cross-
linkers, and whether they are controlled by PKC–Rho signalling
in the cleavage stage mouse embryo.
Our results identifying the asymmetric localisation of the
actomyosin network as the initial step for mouse embryo
polarisation echo the importance of the cortical actomyosin ﬂow
to localise anterior-determining proteins in the Caenorhabditis
elegans zygote60. However, our results also reveal two key dif-
ferences in the relationship between actomyosin and Par complex
polarity between these two model systems. First, we ﬁnd that
upon polarisation of Par complex components, actomyosin
becomes locally reduced and as a result forms a ring structure.
This indicates a negative regulation of actomyosin by Par pro-
teins, in agreement with the failure of actomyosin to form a ring
structure upon elimination of aPKC61. Second, although we show
that an apical contractile myosin meshwork is absolutely required
for apical localisation of the Par complex in the mouse embryo,
just as in the C. elegans embryo, it is not by itself sufﬁcient.
Indeed, we ﬁnd that causing premature actomyosin polarisation
at the 4-cell stage cannot, on its own, trigger apical enrichment of
Par proteins. Thus, polarisation of actomyosin and Par complex
are not necessarily coupled. It is likely that the intact actomyosin
meshwork scaffolds additional factors, which in turn, possibly
through physical binding, allow the Par complex components to
accumulate on the actomyosin-enriched cell-contact-free surface.
The identiﬁcation of such additional factors will present a future
challenge. Together, our results reveal how actomyosin polarisa-
tion breaks symmetry in the mouse embryo to regulate the de
novo establishment of cell polarity in a temporally controlled
manner.
Methods
Animals. This research has been regulated under the Animals (Scientiﬁc Proce-
dures) Act 1986 Amendment Regulations 2012 following ethical review by the
University of Cambridge Animal Welfare and Ethical Review Body (AWERB). For
the collection of embryos, F1 (C57BI6xCBA) females were superovulated by
injecting 7.5 IU of pregnant mares’ serum gonadotropin (PMSG; Intervet), fol-
lowed by the injection of 7.5 IU of human chorionic gonadotropin (HCG; Intervet)
after 48 h. The F1 females were mated with F1 males.
Embryo culture and inhibitor treatments. Embryos were recovered at the 2-cell
stage in M2 medium and transferred to KSOM medium for culture and manip-
ulations, as described previously62. Inhibitors were diluted in KSOM medium and
applied as indicated in each experiment. For controls, the same amount of vehicle
(DMSO or water) was used. Inhibitor concentrations and suppliers are as follows:
D-erythro-sphingosine C-18 (2.5 μM; Caymanchem; in DMSO); Calphostin C (200
nM; Santa Cruz Biotechnology; in DMSO); U73122 (4.5–7.5 μM; Caymanchem; in
DMSO); blebbistatin (25 μM; Sigma-Aldrich; in DMSO); ML-7 (20 μM; Sigma-
Aldrich; in DMSO); Y-27632 (20 μM; Stemcell Technologies);
C3-transferase (7 μg/ml; Cytoskeleton; in distilled water; the zona pellucida of
4–8-cell embryos was removed as described; 1-oleoyl-2-acetyl-sn-glycerol (OAG)
(200 μM; Caymanchem; in DMSO), Latrunculin B (15 μM; Abcam; in DMSO).
Microinjection. The pRN3P vector was used as a backbone as previously descri-
bed63. The mRNA was injected at the stage indicated at the following concentra-
tions: PLCδ1-PH-Ruby (1 μg/μl); Ruby (900 g/μl); GFP-MRLC (600 ng/μl); PKCɑ-
A25E (200 ng/μl); CIBN-Zsgreen-CAAX (400 ng/μl); CIBN-Zsgreen (400 ng/μl);
CRY2-mCherry-PKC-KD (500 ng/μl); GFP-Myl12b-T18DS19D
(600 ng/μl); Raichu-RhoA-CR (600 ng/μl); Clover (200 ng/μl); mRuby2 (200 ng/μl);
RhoA-Q63L (150 ng/μl); CRY2-mCherry-RhoA-Q63L-C190R (600 ng/μl);
Fig. 7 RhoA mediates MRLC and Pard6 cortical polarisation downstream of PLC–PKC signalling. a Scheme of the PLC–PKC rescue experiment using
constitutively active Rho (RhoA-Q63L). b GFP-MRLC overexpressing embryos were injected with Ruby or PLC-DN and immunostained for GFP and Pard6
at the 8-cell stage. Arrowheads indicate the apical domain. c, d Percentage of polarised blastomeres based on either Pard6 (c) or GFP-MRLC (d)
localisation in the groups of (b). N= 17 embryos for Ruby, N= 17 embryos for PLC-DN, N= 18 embryos for PLC-DN + RhoA-Q63L, two independent
experiments. e Scheme of the PLC–PKC rescue experiment using constitutively active Rho (RhoA-Q63L). f GFP-MRLC overexpressing embryos were
treated with DMSO or U73122 and immunostained for GFP and Pard6 at the 8-cell stage. Arrowheads indicate the apical domain. g, h Percentage of
polarised blastomeres based on either Pard6 (g) or GFP-MRLC (h) localisation in the groups of (f). N= 21 embryos for DMSO, N= 17 embryos for U73122,
N= 27 embryos for U73122 + RhoA-Q63L. i Summary model of the signalling events that trigger symmetry breaking and polarisation at the 8-cell stage.
PLC-mediated PIP2 hydrolysis activates PKC to trigger the apical enrichment of myosin II, a subsequent reorganisation of the cortical cytoskeleton and
symmetry breaking. The apical polarisation of myosin II requires both RhoA activation (downstream of PLC–PKC signalling) and MLCK-mediated MRLC
di-phosphorylation. At the late 8-cell stage, the actin-myosin enriched apical cortex recruits Pard6 (directly or indirectly) to the apical domain. For all the
quantiﬁcations, data are shown as a contingency table and the n number in each bar indicates the total number of blastomeres analysed. ****p< 0.0001,
NS= not signiﬁcantly different, Fisher’s exact test. Squares indicate the magniﬁed regions. All scale bars, 15 µm
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CRY2-mCherry (500 ng/μl); Ezrin-Ruby (400 ng/μl); LifeAct-eGFP (300 ng/μl).
Microinjection was performed as previously described63. Brieﬂy, embryos were
placed in a drop of M2 medium on a depression glass slide, covered by parafﬁn oil.
The microinjection was performed with Eppendorf Femtojet microinjector.
Negative capacitance was used to facilitate the membrane penetration of nucleic
acid. After injection, embryos were transferred to KSOM.
Constructs preparation. PLCδ1-PH-Ruby. The PH domain of Plcδ1 was
PCR-ampliﬁed from pBSK-Plcd1-PH-eGFP40 and cloned into the pRN3P vector.
pRN3P-Ruby and GFP-Myl12b. These constructs have been previously
described64.
GFP-Myl12b-T18DS19D: This construct was created by site-directed
mutagenesis using GFP-Myl12b as template.
RhoA-Q63L: RhoA-Q63L was PCR-ampliﬁed from pRK5myc-RhoA-L63 (a
kind gift of Mirna Perez-Moreno65) and inserted into pRN3P vector.
CIBN-Zsgreen and CIBN-Zsgreen-CAAX: The CIBN domain was PCR-
ampliﬁed from pCMV-CIB1-mCerulean-MP (gift of Won Do Heo (Addgene
plasmid #58366)). The Zsgreen was subcloned from pZsgreen-C1 (Clontech) and
inserted downstream of CIBN. The CAAX motif of K-Ras was PCR-ampliﬁed from
mouse liver complementary DNA (cDNA), and inserted downstream of Zsgreen.
CRY2-mCherry-PKC-KD: CRY2 domain and the mCherry coding sequence
were subcloned from pCMV-CRY2-mCherry (gift of Won Do Heo (Addgene
plasmid #58368)) into pRN3P; the kinase domain of PKCɑ (337-673aa) was
PCR-ampliﬁed from pMTH-PKCalpha (gift of Frederic Mushinski (Addgene
plasmid #8409)) and inserted downstream of CRY2-mCherry. PKCɑ-A25E: the
coding sequence of Prkca was PCR-ampliﬁed from pMTH-PKCalpha and cloned
into pRN3P. The A25E mutation was generated by site-directed mutagenesis.
Raichu-RhoA-CR: Raichu-RhoA-CR was subcloned from pCAGGS-Raichu-
RhoA-CR (gift from Michael Lin (Addgene plasmid #40258)) and inserted into
pRN3P.
Clover and mRuby2: Clover or mRuby2 coding sequences were subcloned from
pCAGGS-Raichu-RhoA-CR and inserted into pRN3P vector.
CRY2-mCherry-RhoA-Q63L-C190R: RhoA-Q63L-C190R was generated by
site-directed mutagenesis and inserted into pRN3p-CRY2-mCherry downstream of
mCherry.
Ezrin-Ruby: Ruby was inserted into pRN3P, Ezrin was PCR-ampliﬁed from
mouse adult kidney cDNA and inserted upstream of Ruby.
LifeAct-eGFP: LifeAct peptide coding sequence was cloned into pRN3P
plasmid, eGFP coding sequence was subcloned and inserted downstream of
LifeAct.
Primers for cloning and mutagenesis are in Supplementary Table 1.
Immunoﬂuorescence. Embryos were ﬁxed in 4% paraformaldehyde in PBS for
20 min at room temperature, and washed in PBST (0.1% Tween in PBS) three
times. Embryos were permeabilised in 0.5% Triton X-100 in PBS for 20 min at
room temperature, washed in PBST three times, transferred to blocking solution
(3% bovine serum albumin) for 2 h and incubated with primary antibodies (diluted
in blocking solution) at 4 °C overnight. After the incubation, embryos were washed
in PBST and incubated with secondary antibodies (1:400 in blocking solution) for
1 h at room temperature. Embryos were stained with DAPI (1:1000 dilution, in
PBST, Life Technologies, D3571) for 15 min, followed by two washes in PBST.
Primary antibodies: rabbit polyclonal anti Pard6b (Santa Cruz, sc-67393, 1:200),
rabbit polyclonal anti ppMRLC2 (Cell Signalling, 3674P, 1:200), mouse monoclonal
anti PKCζ (Santa Cruz, sc-17781, 1:50), rabbit polyclonal anti CRB3 (Atlas anti-
bodies, HPA013835, 1:50) and mouse monoclonal anti GFP (Nacalai Tesque Inc.,
04404-84, 1:500). Secondary antibodies: Alexa Fluor 488 donkey anti-rat (Thermo
Fisher Scientiﬁc, A21208), Alexa Fluor 568 donkey anti-rabbit (Life Technologies,
A10042), Alex Fluor 647 donkey anti-rabbit (Life Technologies,
A-21209) and Alexa Fluor 488 Phalloidin (Life Technologies, A12379).
Imaging and data processing. Imaging was done on a Leica-SP5 confocal using a
Leica 1.4 NA 63X oil (HC PL APO) objective. Images were processed with Fiji
software66. For the analysis of cortical ﬂuorescence levels, a line with the width of
0.8 μm overlapping the entire cell-contact-free or cell-contact cortical area was
deﬁned based on the F-actin staining (as illustrated in Supplementary Fig. 1b);
ﬂuorescence levels were determined using the manager tool and plot proﬁle
function in Fiji; signals of different proteins were normalised against the average
signal of the entire area for the plotting. Cortical signal enrichment was calculated
as (Icortex−Icytoplasm)/Icytoplasm. Cell-contact-free enrichment was calculated as
Icell-contact-free/Icell-contact. The length of cell-contact-free domain or Pard6 domain
were measured using freehand line tool and manager tool in Fiji software.
The IEA between adjacent blastomeres was measured as described11.
In live-imaging experiments, time-lapse frames were acquired every 20 min,
using a 3–4 μm Z-step. Images were processed with Fiji software. LOWESS curves
were calculated using R67. Non-linear regression curves were calculated using
Prism software (http://www.graphpad.com).
Optogenetics and regional PKC activation. 2-cell stage embryos were injected
with CIBN-Zsgreen-CAAX and CRY2-mCherry-PKC-KD or CRY2-mCherry-
RhoA-Q63L-C190R or CRY2-mCherry and cultured in the dark. After 3 h,
embryos were transferred to an optical glass bottom culture dish (MatTek Cor-
poration) mounted with M2 medium and imaged under Leica TSC SP5 confocal
microscopy (×63 oil objective). Laser power of 458 nm wavelength (8% for CRY2-
mCherry-PKC-KD and CRY2-mCherry, 4% for CRY2-mCherry-RhoA-Q63L-
C190R) was used to illuminate a deﬁned region in the cell-contact-free domain of
the blastomeres using the region of interest tool in Leica Las AF software. The laser
was illuminated for 5 s and followed with a 20 s interval. Each individual embryo
was imaged for 15 min.
RhoA-FRET imaging and data analysis. The structure of RhoA FRET sensor
Raichu-RhoA-CR was as described previously68. Raichu-RhoA-CR, Clover mRNA
and mRuby2 mRNA were injected into 2-cell stage embryos, and at the 4–8 cell
stage, embryos were imaged under Leica TSC SP8 confocal microscope (Leica
ﬂuotar VISIR 0.95NA ×25 water objective). Images were acquired using the fol-
lowing excitation and emission settings: clover: 488 nm excitation, 505–540 nm
emission; FRET: 488 nm excitation, 580–650 nm emission; mRuby2: 568 nm
excitation, 580–650 nm emission. Clover mRNA-injected embryos and mRuby2
mRNA-injected embryos were imaged ﬁrst to determine the signal bleed-through
(BT). Next, Raichu-RhoA-CR-expressing embryos were imaged with 20 min
interval. For data analysis, the FRET and co-localisation analyser plugins in Fiji
software were used to analyse the co-localisation between donor, FRET and
acceptor channels to eliminate the noise generated by detectors. The radiometric
image of FRET-co-localisation and donor images were generated using the image
calculation function in Fiji. Cell-contact-free/cell-contact RhoA-FRET ratio is
calculated by Icell-contact-free/Icell-contact.
Statistics. Statistical methods are indicated for every experiment in the corre-
sponding ﬁgure legend. Qualitative data is presented as a contingency table and
was analysed using Fisher’s exact test. Normality of quantitative data was ﬁrst
analysed using D’Agostino’s K-squared test. For data showing a normal distribu-
tion, unpaired two-tailed Student’s t test was used to analyse the statistical sig-
niﬁcance (two experimental groups). Differences in variances were taken into
account performing a Welch’s correction. For data that did not present a normal
distribution, a Mann–Whitney U-test (two experimental groups) or a
Kruskal–Wallis test with a Dunn’s multiple comparison test (more than two
experimental groups) were used to test statistical signiﬁcance. Statistical analyses
were performed using Prism software (http://www.graphpad.com).
Data availability. The authors claim that all relevant data of the ﬁndings in this
work are provided within the paper and Supplementary Information ﬁles. Raw data
are available from the corresponding author upon request.
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